A phase III study of cetuximab (CET) plus either brivanib alaninate (BRIV) versus placebo in patients with chemotherapy-refractory KRAS wild-type (WT) advanced colorectal cancer (aCRC): The NCIC CTG/AGITG CO.20 trial.
J. D. Shapiro
Consultant or Advisory Role - Merck Serono (U)
L. L. Siu
Research Funding - Bristol-Myers Squibb
J. R. Zalcberg
Research Funding - Bristol-Myers Squibb; Merck Serono
Other Remuneration - Merck Serono
M. J. Moore
No relevant relationships to disclose
J. Ringash
No relevant relationships to disclose
N. Mittmann
No relevant relationships to disclose
J. Simes
Research Funding - Bristol-Myers Squibb
C. J. O'Callaghan
No relevant relationships to disclose
D. Tu
No relevant relationships to disclose
I. B. Walters
Employment or Leadership Position - Bristol-Myers Squibb
Stock Ownership - Bristol-Myers Squibb
N. Magoski
No relevant relationships to disclose
P. Smith
No relevant relationships to disclose
D. Nomikos
No relevant relationships to disclose
L. Zhu
No relevant relationships to disclose
M. Savoie
No relevant relationships to disclose
S. Virk
No relevant relationships to disclose
F. El-Tahche
No relevant relationships to disclose
R. Gill
No relevant relationships to disclose
T. J. Price
Consultant or Advisory Role - Merck Serono (U)
D. J. Jonker
Consultant or Advisory Role - Amgen (U); Bristol-Myers Squibb (U)
Honoraria - Amgen; Bristol-Myers Squibb